This study established and characterized low-metastatic revertant and parental clones of a highly metastatic human lung cancer cell line, NCI-H460-LNM35 (hereafter referred to as LNM35). Expression-pro®ling analysis revealed that up-regulation of various proinammatory cytokines and angiogenic chemotactic chemokines was present in LNM35. Further, while COX-2 itself is known to be inducible in in¯ammation, COX-2 expression levels correlated well with the capabilities of these clones for not only in vitro motility and invasion but also in vivo metastasis, and COX-2 inhibitors were shown for the ®rst time to reduce lung cancer metastasis in vivo. These ®ndings suggest that lung cancer cells may mimic in¯ammatory cells in the process of metastasis. Oncogene (2001) 20, 4228 ± 4234.
Introduction
Lung cancer has become the leading cause of cancer death in Japan with more than 50 000 deaths annually (Statistics and Information Department, 1998) , and it also claims a great number of lives as the number one cause of cancer death in the United States as well as in many other economically developed countries (Minna et al., 1997; Gazdar et al., 1990) . Despite considerable advances in the understanding of the molecular pathogenesis of lung cancer, only one in eight patients diagnosed as having this disease can be cured at present, while the rest eventually die because of widespread metastases (Minna et al., 1997; Gazdar et al., 1990) . Unfortunately, very little is known about how lung cancer cells propagate distant metastasis and identi®cation of molecules with a crucial role in the distant spread of lung cancer cells has been hampered by scarcity of an appropriate experimental model system.
We recently reported the successful establishment of a highly metastatic human lung cancer cell line, NCI-H460-LNM35 (hereafter referred to as LNM35), which is capable of spontaneous metastases not only via hematogenous but also lymphogenous routes with a 100% incidence (Kozaki et al., 2000) . We made extensive comparative studies of expression levels and/or activities of various adhesion molecules and metalloproteinases, which have been suggested to play a part in the metastatic processes. However, only a single dierence could be identi®ed between LNM35 and its parental NCI-H460, i.e., increased COX-2 expression in LNM35. In addition, signi®cant reduction of motility and invasion of LNM35, although in vitro, was found to be attainable by treatment with a speci®c COX-2 inhibitor, nimesulide.
To gain further insight into the molecular mechanisms of lung cancer metastasis, we established revertant clones with a nearly complete absence of the highly metastatic properties of LNM35 and made a detailed characterization of the biological characteristics of the resulting revertant clones as well as of a representative low-metastatic clone of NCI-H460, a parental line of LNM35. In addition, a comparison of the expression pro®les by cDNA microarray analysis was made in a search for additional genes with dierential expression, which might play a role in the acquisition of the highly metastatic phenotype of LNM35.
Results and Discussion
Establishment and characterization of revertant clones of LNM35 and representative clones of the parental NCI-H460 line
To establish low-metastatic revertant clones from the highly metastatic LNM35 subline, limiting dilution was followed by in vivo examination in SCID mice for the clones' metastasis-forming capabilities. All 11 clones examined in vivo, however, showed a highly metastatic phenotype similar to that of LNM35. We therefore transiently treated LNM35 with either 5-azacytidine or 5-aza-2'-deoxycytidine on the assumption that changes in gene expression could result in loss of the metastatic phenotype. Among the resulting clones obtained after transient treatment with 5-azacytidine, seven were examined in vivo for their metastatic ability in SCID mouse, but none of them showed signi®cant reduction in their metastatic potential. 5-aza-2'-deoxycytidine treatment yielded three clones, which were subsequently examined for metastatic capabilities by subcutaneous inoculation into the¯ank of SCID mice. Two of the three clones were found to have largely lost the metastatic potential of LNM35 and were named L2D2 and L2D3A ( Figure 1A) . In contrast to consistent lymph node metastasis in association with carcinomatous lymphangitis seen in the case of LNM35, neither revertant clone showed any metastasis to axillary lymph nodes, while pulmonary metastases of both revertants were also greatly diminished to less than 10% of LNM35 in both clones. In addition, limiting dilution of the parental NCI-H460 line was also performed. Since all ®ve clones tested in vivo were non-metastatic to lymph nodes and low-metastatic to the lung similarly to NCI-H460 ( Figure 1A , data shown for N15), N15 was chosen as a representative clone for further analyses. Microscopic examination of subcutaneous tumors of L2D2, L2D3A and N15 showed large cell carcinoma characteristics similar to those of LNM35 and NCI-H460 (data not shown).
Further characterization of the low-metastatic clones was carried out in vitro for a comparison with LNM35. They exhibited growth rates similar to that of LNM35, but slightly tighter intercellular junctions ( Figure 1B ). In the in vitro motility and invasion assays, marked dierences were observed between highly metastatic LNM35 and the low-metastatic clones, i.e., the latter shared markedly lower motility and less invasion through the Matrigel than did LNM35 ( Figure 1C ). These ®ndings clearly showed that the two revertant clones, L2D2 and L2D3A, of a highly metastatic LNM35 had lost their invasive and metastatic characteristics to the extent that they resembled N15, a representative clone of the parental line (NCI-H460) of LNM35.
Comparison of expression profiles between highly metastatic LNM35 and low-metastatic N15
To gain insight into the molecular mechanisms of the highly metastatic capability of LNM35, genome-wide screening for the genes dierentially expressed in LNM35 and N15 was performed with the aid of a microarray containing 9844 cDNA fragments. This search consequently identi®ed 13 genes with a more than 2.5-fold up-regulation in LNM35, whereas a more than 2.5-fold down-regulation was detectable in 15 genes (Table 1 ). While our previous study showed increased COX-2 expression in LNM35 and signi®cant inhibition, although in vitro, of its motility and invasion as a result of treatment with nimesulide (Kozaki et al., 2000) , we noted up-regulation of various genes in addition to COX-2 in LNM35 in the present microarray analysis. These included genes known to be related to in¯ammation, including a proin¯ammatory cytokine IL-1a, two C-X-C chemokines (i.e., ENA-78 and NAP-2), complement component 3 and a complement-activating factor, CD55. In addition, our preliminary Northern blot analysis showed increased expression of the IL-1b and IL-1 receptor genes in LNM35, which were not included in the microarray (data not shown). While COX-2 itself is also known to be inducible in the cellular in¯ammatory response (Taketo et al., 1998a,b) , these ®ndings suggest potential eects of the increase in expression of various in¯ammation-related molecules in the acquisition of the highly metastatic capability of LNM35. In this connection, the addition of recombinant IL-1ra, a natural inhibitor of IL-1 (Arend et al., 1991) , was found to signi®cantly reduce in vitro motility and invasion of LNM35 (Figure 2A ), while COX-2 expression was also considerably reduced in the presence of IL-1ra ( Figure 2B ). While the expression of proin¯ammatory cytokines has been suggested to play a role in the metastatic process of a variety of tumor types through various mechanisms (Bani et al., 1991; Vidal-Vanaclocha et al., 1994) , the observations presented here suggest the possibility that COX-2 may be involved as a downstream molecule in the acquisition of the highly metastatic phenotype of LNM35. Interestingly, however, IL-1a-and IL-1b-mediated induction of in vitro motility and invasion in N15 was shown to be very modest ( Figure 2C,D) . Activation of the proin¯ammatory cytokine signaling cascade alone may therefore be insucient for full acquisition of the in vitro invasive and possibly in vivo metastatic phenotypes in this system, so that activation of additional pathways may have been acquired during in vivo selection of LNM35.
In addition, the ENA-78 and NAP-2 chemokines, which were identi®ed as up-regulated in LNM35, can be classi®ed as neutrophil chemotactic C-X-C chemokines with their characteristic ELR motif related to an angiogenic property (Rollins et al., 1997; Wang et al., 1998) , a function partly shared with COX-2 (Taketo et al., 1998a,b) . It is of interest that a study of ENA-78 in lung cancer found that in freshly isolated human specimens of NSCLC, elevated levels of ENA-78 correlated well with the vascularity of the tumors and that neutralizing anti-ENA-78 antibodies reduced tumor growth and vascularity as well as spontaneous metastases in a SCID mouse model (Arenberg et al., 1998) . Our ®ndings suggest that future studies should be of great interest for the comprehensive investigation of the relationships of the expression of proin¯amma-tory cytokines, C-X-C chemokines and their receptors with clinical outcomes of human lung cancer cases, especially in relation to metastasis. In addition to the known genes described here, two ESTs with currently unknown functions were found to be up-regulated in LNM35, which suggests their potential involvement in the acquisition of a highly-metastatic phenotype.
Microarray analysis also revealed that expression of multiple genes known to be involved in cell adhesion was reduced in LNM35, suggesting potential relationships with the looser cell-to-cell contact and highly metastatic phenotype of LNM35. In this regard, various cell adhesion molecules, including E-cadherin, a number of integrins and CD44, have been suggested as being involved in metastatic processes (Sulzer et al., 1998) . Although most of them were contained in the microarray, signi®cant changes in their expression were not observed in LNM35 during the microarray analysis in agreement with our previous observation (Kozaki et . The identi®ed genes with reduced expression in LNM35 included members of the cadherin family (cadherin 11 and BH-protocadherin) and P-selectin ligand CD24 as well as CRIP2, a LIM domain protein highly similar to the zyxin-binding CSRP family members (Huber et al., 2000) . It should be of considerable interest to investigate whether the concerted augmentation of multiple cell adhesion molecule expression may also be present in lung cancer cases, thus enabling these molecules to cooperate in metastasis. It was also noted that cellular dierentiationrelated genes such as the 7B2 protein (neuroendocrine dierentiation), CRIP1 (dierentiation/maturation of intestinal and immune cells) and defensin beta 1 (epithelial dierentiation) appeared to be down-regulated in LNM35, suggesting that LNM35 might be regarded as a more malignant tumor cell with dedierentiated characteristics as is seen during the progression of lung cancers (Wikenheiser et al., 1997) .
Involvement of COX-2 in the invasive and metastatic characteristics of LNM35
The present ®ndings led us to further investigate the involvement of COX-2 in the invasive and metastatic characteristics of LNM35. COX-2 expression was ®rst examined in the low-metastatic parental and revertant clones by means of Northern blot analysis. All the lowmetastatic clones were shown to express COX-2 at signi®cantly lower levels than that of LNM35 ( Figure  3A ). We therefore examined in more detail whether speci®c COX-2 inhibitors could reduce not only in vitro motility and invasion of LNM35 (Kozaki et al., 2000) but also its distant metastasis in vivo. A highly selective COX-2 inhibitor, JTE-522, was found to be potent in the inhibition of invasion through Matrigel as well as of cell motility in a dose-dependent manner at concentrations signi®cantly lower than that required for the inhibition of cell growth ( Figure 3B ). Moreover, it was shown that marked reduction of in vivo metastases to the lung and axillary lymph nodes could be attained as a result of treatment with JTE-522 ( Figure 3C ). The in vivo eects of COX-2 inhibitors were also examined by using another COX-2 inhibitor, nimesulide, in a dierent treatment protocol ( Figure  3D ). In the case of nimesulide, subcutaneous tumors were surgically removed 3 weeks after inoculation and mice were treated with and without nimesulide. Signi®cant reduction of lymph node metastasis was again attained with this COX-2-speci®c inhibitor. Increased COX-2 expression thus appeared to be signi®cantly associated with the in vivo metastatic phenotype of LNM35. It has been suggested that overexpression of COX-2 suppresses apoptosis, resulting in the enhanced tumorigenic potential of rat intestinal epithelial cells (Tsujii et al., 1995) , while COX-2 has been found to possibly play a role in inducing more potent invasiveness of colon cancer cells in vitro (Tsujii et al., 1997) and in the chemotactic response of vascular endothelial cells (Tsujii et al., 1998) . In addition to such reports on the possible involvement of COX-2 in the development of colon cancer, we previously reported that COX-2 is expressed intensely in lung cancer cells in®ltrating into the surrounding stromal tissues as well as in the corresponding lymph node metastases in patients (Hida et al., 1998) and that an increase in COX-2 expression may be associated with a poor prognosis for patients undergoing surgical resection of early stage lung adenocarcinomas (Achiwa et al., 1999) . The present study thus suggests that COX-2 may play a part in the metastatic processes of lung cancers and suggests the potentially clinical usefulness of speci®c COX-2 inhibitors for the treatment of lung cancer cases.
In summary, our ®ndings suggest the possibility that lung cancer cells may mimic in®ltrating in¯ammatory cells in the process of metastasis. Various inhibitors of such in¯ammatory signaling pathways might therefore be useful for the inhibition of metastasis of lung cancers. In this regard, the clear association of in vivo metastasis with in vitro motility and invasion identi®ed in our system suggests that high-throughput in vitro screening with the use of highly metastatic and lowmetastatic clones may be feasible for the identi®cation of small molecules with a metastasis-inhibiting capability. Finally, further genome-wide, expression-pro®l-ing analytical studies using LNM35 and the lowmetastatic clones with the aid of cDNA microarrays with a larger size are warranted, in order to identify novel molecular targets for the treatment of this fatal disease.
Materials and methods

Animals and cell lines
Five-week-old female athymic nude mice and SCID mice were purchased from the Shizuoka Laboratory Animal Center (Hamamatsu, Japan) and maintained under speci®c-pathogen-free conditions. Establishment of LNM35, a highly metastatic subline of the NCI-H460 human large cell lung cancer cell line, has been reported previously (Kozaki et al., 2000) . Representative clones of the parental NCI-H460 line were isolated by limiting dilution of NCI-H460. To obtain low-metastatic revertant clones, LNM35 was transiently treated with either 10 mM of 5-azacytidine or 1 mM of 5-aza-2'-deoxycytidine for 24 h. Independent clones were selected by means of limiting dilution and examined for in vivo metastasis in SCID mice as described below. All cell lines were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum.
Spontaneous metastasis assay 1.0610 7 cells in 100 ml of serum-free RPMI 1640 medium were injected in the subcutaneous tissue of the left abdominal wall of 7-week-old female SCID mice or nude mice. Forty days after subcutaneous injection, mice were sacri®ced by cervical dislocation under deep anesthesia and their lungs, lymph nodes and subcutaneous tumors resected. The resected specimens were weighed, ®xed with 4% paraformaldehyde and processed for light microscopic examination of the paran-embedded sections stained with hematoxylin and eosin. The lung-metastatic nodules were examined and counted under a dissecting microscope.
Tumor-bearing SCID mice were treated with the aid of either a diet containing 0.5% JTE-522 or drinking water containing 500 ppm of nimesulide, followed by the assessment of metastases 33 days after the subcutaneous injection. On the basis of the daily consumption of the diet and drinking water, the average doses of JTE-522 and nimesulide could be calculated as 100 and 80 mg/kg/day, respectively. JTE-522 was provided by Japan Tobacco Inc. (Tokyo, Japan) and nimesulide by Hisamitsu Pharmaceutical Co. (Tosu, Japan).
In vitro motility and invasion assay
To quantify in vitro motility and invasion, transwell-chamber culture systems were used. The upper surface of 6.4-mmdiameter ®lters with 8-micrometer pores (Becton Dickinson Labware, Franklin Lakes, NJ, USA) were coated with 100 ml of 0.1 mg/ml Matrigel (Collaborative Research Inc., Bedford, MA, USA) for the invasion assay. The ®lters were then ®lled with 0.5 ml of serum-free RPMI 1640 medium and placed on culture plates with 24 wells containing 1 ml of the medium. Cells (1610 4 cells for the motility assay, 1610 5 cells for the invasion assay) were then added to the upper chambers and cultured. Following 24 h of incubation, the ®lters were ®xed with 70% ethanol and stained with giemsa, and the cells on the lower surface of the ®lters counted in triplicate.
Expression profiling
Polyadenylated RNA was isolated from LNM35 and N15 cells with the OligoTex (Qiagen, Valencia, CA, USA) RNA kit. Polyadenylated RNA from LNM35 and N15 cells was reverse transcribed to generate Cy3-and Cy5-labeled cDNA probes, respectively. cDNA probes were competitively hybridized to a human UniGEM (version 2.0) cDNA microarray (Incyte Pharmaceuticals Inc., Palo Alto, CA, USA) containing 9844 immobilized cDNA fragments. Cy3 and Cy5¯uorescence were imaged individually, and the normalized ratios of Cy3/Cy5¯uorescence at a given spot on the microarray were used to calculate dierential gene expression. Northern blot analysis was performed as described previously (Kozaki et al., 2000) .
